Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multicentered, Open-label Phase 2 Clinical Trial of the Safety and Efficacy of Human Coronavirus- Immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children

NCT04377568 is registered in ClinicalTrials.gov with The Hospital for Sick Children as lead sponsor.

NCT NCT04377568
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04377568 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multicentered, Open-label Phase 2 Clinical Trial of the Safety and Efficacy of Human Coronavirus- Immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children
Lead sponsor
The Hospital for Sick Children
Phase
Phase 2
Overall status
Withdrawn
Start date
October 7, 2020
Completion date
May 1, 2022
Enrollment
0 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 infection, hospitalized children